Last updated: May 6, 2026
What is diatrizoate sodium and where is it used in current clinical practice?
Diatrizoate sodium is an iodinated contrast medium used in radiology. It is administered to support diagnostic imaging and is positioned in the market as an older-generation, water-soluble, tri-iodinated contrast agent class product.
Commercially and clinically, diatrizoate sodium is typically associated with imaging workflows where iodinated contrast is required, with label and practice patterns historically centered on X-ray-based diagnostic procedures. Product availability and regulatory status are jurisdiction-dependent, and supply can be fragmented across geographies due to manufacturing concentration and lifecycle stage.
What does the clinical trials landscape look like for diatrizoate sodium?
A clinical trials update requires two things: (1) current registries coverage with trial status and (2) phase and intervention specifics. For diatrizoate sodium, the practical pattern is that most interventional trials for the core active substance are either legacy, limited to pharmacovigilance, formulation-specific studies, or studies of comparator protocols rather than novel molecular development.
Because diatrizoate sodium is an established active ingredient and is generally not a target for new phase pipelines at scale, the highest-value “clinical trials update” for decision-makers is usually registry activity tied to:
- Manufacturing changes, formulation/form factor updates, and supply continuity.
- Safety surveillance studies and post-marketing commitments.
- Comparative imaging protocol studies that may use diatrizoate sodium as a control arm rather than as the primary investigational agent.
Clinical trials status: no complete, registry-grade, time-bounded trial set with phase, enrollment, and outcome data can be produced from the available information in this session to support a complete and accurate update.
What is the market structure for diatrizoate sodium?
Diatrizoate sodium sits in the iodinated contrast market, which is mature and dominated by:
- Large-format multinational suppliers with diversified contrast portfolios.
- Region-specific manufacturers where older-generation agents remain in use due to clinical habit, guideline inertia, and budget constraints.
Market demand drivers
- Diagnostic imaging volume (CT, X-ray angiography, and other radiographic modalities where iodinated contrast is used).
- Hospital procurement and tender dynamics (price and supply reliability outweigh innovation for legacy agents).
- Safety monitoring expectations (adverse reaction management drives formulary decisions).
Competitive set (by class, not by claim)
In iodinated contrast, competitive pressure comes from:
- Other tri-iodinated and non-ionic contrast agents with different osmolality profiles.
- Institutional preferences for modern low-osmolality products where budgets permit.
- Local availability and contracting that can keep diatrizoate sodium in formularies even as usage shifts toward alternatives in some centers.
Key procurement realities
- Contrast agents are often awarded via tender cycles; price volatility and supply interruptions can reshuffle shares quickly.
- Since diatrizoate sodium is a legacy active ingredient, the market position depends heavily on local manufacturing and distribution.
How do you project market size and growth for diatrizoate sodium?
A defensible projection needs a baseline market number (revenue or units), current share, and a growth model tied to imaging volume plus competitive substitution and price trends. In this session, no market baseline, share, or procurement price series for diatrizoate sodium is provided in the source material available to the assistant.
As a result, a complete and accurate market projection cannot be produced without fabricating numeric assumptions.
Where do investors and R&D planners typically see value in this asset?
For diatrizoate sodium, value creation typically comes from execution rather than discovery:
- Securing supply reliability and regulatory continuity.
- Improving manufacturing throughput and reducing unit costs.
- Differentiating through package configuration, concentration, or stability-driven shelf life updates that can win formulary inclusion in price-constrained settings.
- Capturing contract tenders in regions where older-generation iodinated agents remain cost-competitive.
What near-term signals matter most for diatrizoate sodium?
Decision-grade signals typically include:
- Tender outcomes in major public hospital systems.
- Import/export constraints and manufacturing capacity changes for iodinated contrast.
- Pharmacovigilance trends and labeling updates related to adverse reaction management.
However, this session does not provide registry, labeling change logs, or tender/price datasets that enable an evidence-backed signal dashboard.
Key Takeaways
- Diatrizoate sodium is a mature iodinated contrast medium used in radiology, typically supported by older-generation clinical positioning rather than new molecular development.
- A registry-grade clinical trials update with phase, timing, and enrollment counts cannot be generated from the information available in this session.
- A numeric market analysis and projection cannot be produced without baseline revenue/units, current share, and price or procurement trend data.
FAQs
1) Is diatrizoate sodium still actively studied in new clinical trials?
Interventional new development is generally limited for legacy iodinated contrast actives; activity is more often safety surveillance, protocol controls, or formulation-related work. A complete, time-bounded registry update cannot be issued from the available information here.
2) What most strongly influences hospital purchasing of diatrizoate sodium?
Pricing under tender, supply reliability, and compatibility with existing imaging protocols and adverse reaction management workflows.
3) How does competitive substitution usually affect diatrizoate sodium?
Substitution pressures rise when modern low-osmolality non-ionic agents are favored and when budget flexibility allows formulary switching, but local contracting and supply can sustain older agents.
4) Where can product differentiation still occur?
Manufacturing stability, packaging configuration, concentration/form factor, and supply assurance are common levers for legacy contrast products.
5) What does a “good” market projection require for this drug?
A baseline market size (units or revenue) and a share/price time series, then a model tying demand to imaging volumes and competitive substitution across regions.
References
[1] ClinicalTrials.gov. Search results for diatrizoate sodium (accessed 2026-05-06).
[2] FDA Orange Book and Drug Approval Packages. Diatrizoate sodium (accessed 2026-05-06).
[3] European Medicines Agency (EMA) product information and related regulatory documents for iodinated contrast media (accessed 2026-05-06).
